IMCI is well-positioned to lead the next evolution of the cannabis medication with its patented and effective cannabinoid-based treatments to treat chronic indications.

Aiming at large and fast-growing markets with a potential of 20% CAGR, and an estimated value of US$ 13 Bn by 2028 (in Israel, Europe, and the USA).

​

​

Join us and be part of this new and exciting development.